25 October 2016 -  Draft guidance supports the use of both bDMARDs.

Certolizumab pegol alone, or in combination with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults only if:

• it is used as described for the tumour necrosis factor (TNF) inhibitor treatments in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis, or
  
• the person has had a TNF-alpha inhibitor but their disease has stopped responding after the first 12 weeks and
  
• the company provides certolizumab pegol as described in the proposed patient access scheme.
  

Secukinumab alone, or in combination with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults only if:

• it is used as described for the tumour necrosis factor (TNF) inhibitor treatments in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis or
  
• the person has had a TNF-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or
  
• TNF-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis) and
  
• the company provides secukinumab with the discount agreed in the patient access scheme.
  

Read NICE draft guidance